AstraZeneca to Buy Icosavax for Up to $1.1 Billion -- Update
December 12 2023 - 2:02AM
Dow Jones News
By Ian Walker
AstraZeneca said it would buy U.S.-based clinical-stage
biopharmaceutical company Icosavax for up to $1.1 billion in a deal
that expands its vaccines and immune therapies late-stage
pipeline.
The pharmaceutical giant is offering $15 for each Icosavax share
held, a 43% premium to its closing market price of $10.49 on
Monday.
An extra $5.00 a share in cash could be paid depending upon
certain regulatory and sales milestones being met.
Icosavax has a protein virus-like particle platform technology
used to develop vaccines against infectious diseases. Its initial
focus is on life-threatening respiratory diseases, with a vision
for combination and pan-respiratory vaccines.
"With the addition of Icosavax's Phase 3-ready lead asset to our
late-stage pipeline, we will have a differentiated, advanced
investigational vaccine, and a platform for further development of
combination vaccines against respiratory viruses," said
AstraZeneca's executive vice president, Vaccines & Immune
Therapies, Iskra Reic.
AstraZeneca said it expects the acquisition to close in the
first quarter of 2024.
Write to Ian Walker at ian.walker@wsj.com
(END) Dow Jones Newswires
December 12, 2023 02:47 ET (07:47 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
Icosavax (NASDAQ:ICVX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Icosavax (NASDAQ:ICVX)
Historical Stock Chart
From Jul 2023 to Jul 2024